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Abstract
Introduction: Discordant lymphomas are rare entities characterized by the simultaneous presence of two distinct
types of lymphomas in different anatomic sites. We describe a very rare case of simultaneous occurrence of splenic
mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood.
Case presentation: We report the case of a 60-year-old asymptomatic Caucasian woman in whom discordant
lymphomas were discovered when a slight lymphocytosis and a conspicuous splenomegaly were observed. The
different morphological, immunophenotypical and immunohistochemical features found in the different pathologic
samples obtained from peripheral blood, bone marrow and spleen sections made it possible to differentiate two
types of non-Hodgkin B-cell lymphomas: a mantle cell lymphoma infiltrating the spleen and a marginal zone
lymphoma involving both the bone marrow and peripheral blood. Since a similar IgH gene rearrangement was
found both in the bone marrow and in the spleen, the hypothesis of a common origin, followed by a different
clonal selection of the neoplastic lymphocytes may be taken into consideration.
Conclusion: Our case emphasizes the usefulness of investigating simultaneous specimens from different anatomic
sites from the same patient and the relevant diagnostic role of splenectomy.
Introduction
The association of two distinct B-cell non-Hodgkin lym-
phomas in the same patient and involving different ana-
tomical locations is a rare phenomenon. This peculiar
presentation, called ‘discordant lymphoma’,h a st ob e
differentiated from the so-called ‘composite lymphoma’,
which is the occurrence of two or more morphologically
and immunophenotypically distinct lymphoma clones in
a single anatomical site, that is within a single organ or
tissue [1].
We describe a patient with mantle cell lymphoma
(MCL) concomitant with a marginal zone lymphoma
(MZL). The former was responsible for massive spleno-
megaly, while the latter was responsible for bone mar-
row infiltration and peripheral blood spread. A
multidisciplinary approach was necessary for diagnosis,
but splenectomy proved to be of particular relevance
both for detecting the localization of MCL in our
patient and for choosing the most appropriate therapy.
Case presentation
A 60-year-old Caucasian woman who had a silent clini-
cal history with the exception of obesity and mild dia-
betes had routine blood count and chemistry tests at the
recommendation of her family doctor. A slight lympho-
cytosis (range: 4.0 to 4.5 × 10
9/L) was observed. All the
other blood parameters, including white blood cells,
hemoglobin, hematocrit, platelet count, lactate
* Correspondence: giovannicarulli@alice.it
1Department of Oncology, Transplants and New Technologies in Medicine,
Division of Hematology and Section of Flow Cytometry, University of Pisa,
Pisa, Italy
Full list of author information is available at the end of the article
Carulli et al. Journal of Medical Case Reports 2011, 5:476
http://www.jmedicalcasereports.com/content/5/1/476 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Carulli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.dehydrogenase, plasma proteins, protein electrophoresis,
and immunoglobulin levels, were within the normal
range. Serum immunofixation was negative. Immunophe-
notyping of peripheral blood samples was carried out by
flow cytometry using a FacsCanto II cytometer (Becton
Dickinson) equipped with two lasers (488 and 633 nm).
Samples (50 μL) were stained with fluorochrome-conju-
gated monoclonal antibodies (MoAbs) specific for the
following antigens: CD3, CD4, CD8, CD5, CD16, CD56,
CD19, CD20, CD22, CD23, FMC7, CD103, CD11c,
CD25, CD10, CD38, CD45 (purchased from Becton Dick-
inson), and K and l immunoglobulin light chains (pur-
chased from Dako). A six-color panel was used for each
tube, associating MoAbs conjugated with FITC, PE,
PerCP-Cy5.5, PE-Cy.7, APC and APC-Cy.7. At least
200,000 events were acquired and data were processed
u s i n gF a c s D i v as o f t w a r e( B e c t o nD i c k i n s o n ) .L y m p h o -
cytes were gated using CD45 expression and right angle
scatter. A second gate included CD19+ events and was
used to analyze the expression of the other markers.
Immunophenotyping showed an excess of B-lympho-
cytes (1.5 × 10
9/ L )w i t hb r i g h te x p r e s s i o no fC D 2 0a n d
CD22, restriction for the K light chain of surface immu-
noglobulins, and absence of CD5 and CD10 (Figure 1).
At light microscopy, lymphocytes were not villous (not
shown).
A whole body computed tomography showed spleno-
megaly (20 cm longitudinal axis), but no lymphoadeno-
megaly or signs of other organ involvement were found.
The patient was referred to the Division of Hematol-
ogy for further observation and underwent bone marrow
evaluation (morphology by myeloaspirate specimens, tre-
phine biopsy, flow cytometry, molecular biology assays
and karyotype).
Bone marrow trephines were fixed in Myelodec
®
reagent A (Bio-Optica) for two hours, decalcified in
EDTA for two days, embedded in paraffin, and cut into
3t o5μm sections. Morphological evaluations were per-
formed on hematoxylin-eosin, Giemsa and Gordon-
Sweet for reticulin-stained sections. Immunohistochem-
ical stainings were performed using a peroxidase-based
system including antibodies specific for: CD20, CD3,
CD5, CD23, DBA44, bcl2, bcl6, and cyclin-D1 (DSC-6).
The spleen was sectioned and fixed in buffered formalin.
Figure 1 Flow cytometry of peripheral blood lymphocytes. CD19-positive lymphocytes are CD5- (A), and CD20+ and CD22+ (B, C),B -
lymphocytes show restriction for surface K light chain (D) and are CD10-negative (E). Negativity for CD5 is confirmed by the use of another
anti-CD5 monoclonal antibody (F).
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cellularity of 50% with nodular-interstitial infiltration by
CD20+ and bcl2+ lymphocytes, which accounted for
15% of cellularity and was negative for CD5, CD23, bcl-
6, cyclin-D1 and DBA44 (Figure 2).
Flow cytometry of bone marrow blood showed 16%
lymphocytes which were positive for CD19, CD20,
CD22, CD103 and surface K light chain, and negative
for CD5, CD23, CD10, CD11c, CD25, and surface l
light chain (Figure 3).
Mononuclear cells were separated by Ficoll/Hypaque
gradient from bone marrow and peripheral blood sam-
ples, and suitable aliquots were utilized for polymerase
chain reaction (PCR) tests after spectrophotometric
quantitative evaluation. Fluorescent PCR reactions for
IgH clonality evaluation were carried out with CDR3-
specific VH consensus primer and analyzed by ABI
PRISM 3100 (Applied Biosystems) [2]), whereas the
results of FRI VH region rearrangement amplifications
were run on a 3.5% agarose gel. Qualitative PCR detect-
ing Bcl-1/JH rearrangements were performed according
Figure 3 Flow cytometric evaluation of bone marrow. The neoplastic lymphocytes are positive for CD19, CD20, CD22, surface K light chain,
FCM7, CD103, and negative for CD5, CD10, surface l light chain, CD11c, CD25, CD23.
Figure 2 Bone marrow histology. A hematoxilin and eosin-stained
section showing a discrete lymphocytic infiltrate, composed of small
B cells as highlighted by anti-CD20 immunostaining (B). Only a
small percentage (fewer that 10%) of these cells are CD5-positive
(C) or express cyclin D1 (D). The immunoprofile suggests a possible
marginal origin for neoplastic lymphocytes. Magnification: 100×.
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(BIOMED-2 Concerted Action) [3].
T h em o l e c u l a rf i n d i n g ss h o w e das i n g l ec l o n a lr e a r -
rangement of the IgH gene and the absence of the bcl-
1/JH translocation.
Karyotyping was carried out by conventional banding
methods and no pathologic metaphases were detected
by conventional karyotype.
Diagnosis of B-cell non-Hodgkin lymphoma, compati-
ble with the MZL subtype, was therefore made.
The patient underwent splenectomy to remove a sig-
nificant burden of disease and to confirm the initial
diagnosis. Macroscopic examination showed that the
organ was 23 × 15 × 8 cm, with a weight of 1350
grams. The spleen was sectioned and fixed in buffered
formalin. Several samples were routinely processed to
paraffin wax and sections of 3 to 5 μmw e r es t a i n e d
with hematoxylin-eosin for morphological evaluation. A
panel of antibodies (CD20, CD3, CD5, CD10, CD23,
bcl2, bcl6, cyclin-D1, CD10 and Ki-67) was applied to
some samples using the ultraView Universal DAB
Detection Kit and blue reagent with a BenchMark XT
Automated Slide Stainer (Ventana).
The spleen was found to be infiltrated by a MCL; lym-
phocytes were positive for CD20, CD5, bcl2, negative for
CD23 and CD10, had a low mitotic index (Ki-67: 5 to
10%), and showed a strong positivity for cyclin-D1 and a
characteristic pattern of infiltration (Figure 4). The neo-
plastic lymphocytes were seen as small to medium-sized
cells with irregular nuclear contours, giving rise to a
mantle-fashion pattern of infiltration. DNA extracted
from paraffin-embedded spleen specimens (EZ1
Advanced, Qiagen) was subjected to PCR assays, which
showed a clonal IgH rearrangement, the same as found
in the bone marrow (Figures 5 and 6).
At the end of our evaluation, the patient was diag-
nosed as suffering from the simultaneous presence of
splenic MCL and bone marrow MZL with peripheral
blood expression. Therapy with the cyclophosphamide,
hydroxydaunorubicin (Adriamycin), Oncovin (vincris-
tine) and prednisone - rituximab (CHOP-R) protocol
was started and, after six courses and restaging by com-
puted tomography and bone marrow and peripheral
blood investigation, showed that complete remission
was achieved.
Discussion
Composite lymphomas involving a MCL and another
type of B-cell non-Hodgkin lymphoma have sometimes
been described [4], but the occurrence of discordant
lymphomas seems to be rarer. In 2007 Goteri et al. [5]
described the first case of a nodal MCL associated with
a cutaneous follicular lymphoma.
We describe the case of a patient with discordant lym-
phoma characterized by the coexistence of splenic MCL
and a CD5-negative non-Hodgkin lymphoma involving
both the bone marrow and peripheral blood and compa-
tible with a MZL.
The first pathologic finding in our patient was a very
mild lymphocytosis with the presence of a clone of non-
villous circulating B-cells,w h i c hw e r en e g a t i v ef o rC D 5
and for bcl-1/JH translocation. A prominent splenome-
galy was detected only after computed tomography,
since the patient was asymptomatic and without any
Figure 5 Qualitative RT-PCR for IgH. Rearrangement of IgH was
assessed on the splenic sections (lane 1) and on the bone marrow
(lane 2) with VH families-specific primers. Run on 3.5% agarose gel.
The amplification pattern was the same (arrows).
Figure 4 Spleen sections. (A) Expansion of the white pulp, which
is composed of small or medium-sized elements showing variable
morphology of the nucleus and pale cytoplasm. The red pulp is
colonized and congested (H&E). (B-D) CD20, CD5 and Cyclin D1
expression. Magnification: 100×
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Tomography did not show nodal involvement or other
sites suspected of disease localization.
The demonstration of a mild bone marrow involve-
ment due to CD5-negative B-lymphocytes which were
also CD103+, and negative for CD25, bcl-1/JH, and t
(11;14), was consistent with a first hypothesis of sple-
nic MZL. MZL are indolent B-cell diseases that puta-
tively originate from the marginal zone of B-cell
follicles, and can be found in the spleen, lymph node,
and mucosal lymphoid tissues. Splenic MZL is a dis-
tinctive form of indolent lymphoma originating in the
spleen, characterized by prominent splenomegaly and
variable involvement of lymph nodes, bone marrow,
peripheral blood, and other organs. Bone marrow infil-
tration is almost constant (83% to 100% of cases),
while peripheral blood is involved in 29% to 75% in
the various series [6]. MZL does not have a genetic
signature. Unlike other types of non-Hodgkin lym-
phoma, such as follicular lymphoma and MCL, cytoge-
netic findings are not specific, so a diagnosis of MZL
is made providing that other small B-cell lymphomas
are excluded. The pattern of spleen infiltration pro-
vides the best diagnostic piece of information and sple-
nectomy represents a very useful diagnostic tool. The
immunophenotype of MZL lacks typical markers. CD5
Figure 6 Qualitative fluorescence PCR of IgH rearrangement. Rearrangement of IgH was assessed on the splenic sections (lane #1) and on
the bone marrow (lane 2). The length of the PCR product (93 bp) was the same in both organs (arrows).
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CD103+/CD25- has been suggested as a good diagnos-
t i cf e a t u r e[ 7 ] .
In our patient splenectomy was carried out both to
confirm our provisional diagnosis and to remove a sig-
nificant burden of disease. The spleen was infiltrated by
MCL, with typical morphologic and phenotypic features
(CD5+, cyclin D1+) [8].
Splenomegaly is a frequent finding in MCL (about
50% of cases) [9] and is usually associated with other
disease localizations and variable outcome. Angelopou-
lou et al. [10] described a splenomegalic form of MCL
with bone marrow infiltration and peripheral blood
spread in which the infiltrating lymphocytes showed
similar phenotypic features both in the spleen and in
the bone marrow, and peripheral blood lymphocytes
showed atypical morphology and the phenotype of
MCL. The clinical course of such patients is more indo-
lent than the common type of MCL and splenectomy is
able to induce a partial regression of the disease.
In MCL, bone marrow involvement is a common find-
i n g ,w h i l eal e u k e m i cp r e s e n t a t i o ni sm o r ev a r i a b l ea n d
often associated with poor prognosis [11].
In our patient, the splenic findings, including mor-
phology, immunophenotype and immunohistochemistry,
were strongly consistent with MCL [8]. The clinical pre-
sentation of our patient, with asymptomatic disease and
splenic involvement discovered accidentally, was very
similar to the cases described by Angeloupolou et al.
[10]. On the other hand, the characteristics of the neo-
plastic lymphocytes found in the bone marrow and in
peripheral blood did not satisfy the common criteria for
MCL [8], since they were CD5-negative, CD103-positive,
cyclin-D1-negative, bcl-1/JH-negative and t(11;14)-nega-
tive. The most probable diagnosis was that of a simulta-
neous occurrence of a splenic MCL and a MZL, with
the latter involving the bone marrow and peripheral
blood.
An alternative diagnosis might be an association of
MCL involving the spleen and an atypical MCL invol-
ving both bone marrow and peripheral blood.
Indeed, MCL shows immunophenotypic variations. It
is known that some cases (about 10%) of MCL can be
CD5-negative, or bcl-1/JH-negative (ranging from < 10%
to 40%), or t(11;14)-negative (up to 50%) [12,13].
Cyclin-D1 positivity in the absence of CD5 expression
makes a diagnosis of CD5-negative MCL more likely
[14], due to the high diagnostic specificity of the former
marker.
Thus, the simultaneous negativity for all the diagnostic
markers of MCL seemed to exclude a diagnosis of MCL
in the bone marrow. In addition, the immunophenotype
of circulating lymphocytes was similar to that of bone
marrow neoplastic cells.
The presence of the same IgH rearrangement both in
bone marrow and in the spleen could suggest the
hypothesis of a common origin of neoplastic lympho-
cytes, which might have undergone a different clonal
selection, followed by the acquisition of two different
phenotypes.
Therefore, the final diagnosis of a discordant lym-
phoma consisting of splenic MCL and bone marrow
MZL with leukemic spread was established.
Conclusions
Our case emphasizes the role of both the simultaneous
investigation of specimens from different sites from the
same patient and splenectomy in the diagnosis of cases
of B-cell lymphomas with marked splenomegaly. In our
patient, a wrong diagnosis would have been made with-
out splenic histologic examination, leading to an erro-
neous therapy. In fact, splenic MZL is often treated with
non-aggressive regimens including [15,16], while therapy
of MCL involves more aggressive regimens, such as
hyper-cyclophosphamide, vincristine, Adriamycin (dox-
orubicin) and dexamethasone (CVAD) or FCM, possibly
associated with anti-CD20 MoAb [17]. MCL cases with
marked splenomegaly but without nodal involvement
can be treated with less aggressive regimens because of
their more indolent behavior. We decided to use the R-
CHOP schedule and a very good result was obtained,
since disease restaging showed complete remission.
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